Recombinant Paraprobiotics as a New Paradigm for Treating Gastrointestinal Nematode Parasites of Humans.

Bacillus thuringiensis anthelmintic crystal protein gastrointestinal nematodes helminths hookworms paraprobiotic soil-transmitted helminths

Journal

Antimicrobial agents and chemotherapy
ISSN: 1098-6596
Titre abrégé: Antimicrob Agents Chemother
Pays: United States
ID NLM: 0315061

Informations de publication

Date de publication:
17 02 2021
Historique:
received: 10 07 2020
accepted: 08 12 2020
pubmed: 16 12 2020
medline: 22 6 2021
entrez: 15 12 2020
Statut: epublish

Résumé

Gastrointestinal nematodes (GINs) of humans, e.g., hookworms, negatively impact childhood growth, cognition, nutrition, educational attainment, income, productivity, and pregnancy. Hundreds of millions of people are targeted with mass drug administration (MDA) of donated benzimidazole anthelmintics. However, benzimidazole efficacy against GINs is suboptimal, and reduced/low efficacy has been seen. Developing an anthelmintic for human MDA is daunting: it must be safe, effective, inexpensive, stable without a cold chain, and massively scalable.

Identifiants

pubmed: 33318013
pii: AAC.01469-20
doi: 10.1128/AAC.01469-20
pmc: PMC8092541
pii:
doi:

Substances chimiques

Anthelmintics 0
Bacterial Proteins 0

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : NIAID NIH HHS
ID : R01 AI056189
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI150866
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI015066
Pays : United States

Informations de copyright

Copyright © 2021 Li et al.

Références

Proc Natl Acad Sci U S A. 2004 Jul 27;101(30):10995-1000
pubmed: 15256590
Int J Parasitol Drugs Drug Resist. 2020 Dec;14:230-236
pubmed: 33242790
Front Microbiol. 2018 Aug 23;9:1915
pubmed: 30190709
Curr Protoc Immunol. 2003 Aug;Chapter 19:Unit 19.12
pubmed: 18432905
ACS Nano. 2015 Jun 23;9(6):6158-67
pubmed: 25950754
Parasitology. 1989 Apr;98 Pt 2:283-9
pubmed: 2762039
Nat Biotechnol. 2017 Oct 11;35(10):926-935
pubmed: 29020006
Acta Trop. 2003 May;86(2-3):141-59
pubmed: 12745134
Biotechnology (N Y). 1995 Jan;13(1):67-71
pubmed: 9634751
PLoS One. 2013 Jul 15;8(7):e70702
pubmed: 23869246
Sci Rep. 2019 Aug 26;9(1):12347
pubmed: 31451730
Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2760-5
pubmed: 12598644
Emerg Infect Dis. 2014 Jun;20(6):976-82
pubmed: 24865815
Science. 2005 Feb 11;307(5711):922-5
pubmed: 15705852
Adv Parasitol. 2010;73:197-230
pubmed: 20627144
J Environ Sci Health A Tox Hazard Subst Environ Eng. 2019;54(7):608-616
pubmed: 30821189
J Am Mosq Control Assoc. 2002 Mar;18(1):57-62
pubmed: 11998932
Ann N Y Acad Sci. 2008;1136:38-44
pubmed: 17954674
Am J Trop Med Hyg. 2011 May;84(5):792-800
pubmed: 21540391
PLoS Negl Trop Dis. 2010 Mar 02;4(3):e614
pubmed: 20209154
J Health Econ. 2016 May;47:20-33
pubmed: 26928437
Front Plant Sci. 2015 Apr 29;6:283
pubmed: 25972882
Ultrason Sonochem. 2019 Oct;57:12-21
pubmed: 31208607
PLoS Negl Trop Dis. 2011 Dec;5(12):e1457
pubmed: 22216366
PLoS Negl Trop Dis. 2012;6(4):e1608
pubmed: 22509421
Int J Parasitol Drugs Drug Resist. 2018 Aug;8(2):287-294
pubmed: 29772478
J Infect Dev Ctries. 2014 Jan 15;8(1):5-16
pubmed: 24423707
Lancet. 2006 May 6;367(9521):1521-32
pubmed: 16679166
Parasit Vectors. 2014 Jan 21;7:37
pubmed: 24447578
Methods Mol Biol. 2006;351:139-54
pubmed: 16988432
Am J Trop Med Hyg. 2017 Feb 8;96(2):347-354
pubmed: 27895280
Trans R Soc Trop Med Hyg. 2009 Oct;103(10):1031-44
pubmed: 19409588
Am J Trop Med Hyg. 2013 Sep;89(3):540-8
pubmed: 23836564
Regul Toxicol Pharmacol. 2000 Oct;32(2):156-73
pubmed: 11067772
PLoS Negl Trop Dis. 2013 Jun 20;7(6):e2263
pubmed: 23818995
Proc Natl Acad Sci U S A. 2010 Mar 30;107(13):5955-60
pubmed: 20231450
Toxicol Pathol. 2015 Feb;43(2):272-81
pubmed: 24771081
Appl Environ Microbiol. 2013 Sep;79(18):5527-32
pubmed: 23835175
Genes Nutr. 2011 Aug;6(3):261-74
pubmed: 21499799
Int J Parasitol Drugs Drug Resist. 2017 Dec;7(3):262-271
pubmed: 28697451
Appl Microbiol Biotechnol. 2018 Dec;102(23):10209-10218
pubmed: 30288586
Bioessays. 2005 Jun;27(6):614-24
pubmed: 15892110
FEMS Microbiol Lett. 1989 Jul 15;51(1):211-7
pubmed: 2550317
PLoS Pathog. 2011 Mar;7(3):e1001314
pubmed: 21408619
Genetics. 1974 May;77(1):71-94
pubmed: 4366476
Proc Natl Acad Sci U S A. 2006 Oct 10;103(41):15154-9
pubmed: 17005719
Genetics. 2000 Aug;155(4):1693-9
pubmed: 10924467
Molecules. 2020 Jun 27;25(13):
pubmed: 32605043
PLoS Negl Trop Dis. 2012 Jan;6(1):e1417
pubmed: 22235353
Emerg Infect Dis. 2017 Feb;23(2):252-257
pubmed: 28098526
Int J Parasitol. 1993 Nov;23(7):945-52
pubmed: 8106187
Parasitology. 2007 Jan;134(Pt 1):103-12
pubmed: 17032468
PLoS Negl Trop Dis. 2018 May 18;12(5):e0006506
pubmed: 29775454
J Parasitol. 1994 Feb;80(1):24-8
pubmed: 8308654
Nutr Res Rev. 2010 Jun;23(1):37-46
pubmed: 20403231
PLoS One. 2011;6(12):e29122
pubmed: 22216181
PLoS One. 2010 Mar 02;5(3):e9494
pubmed: 20209166
JAMA. 2008 Apr 23;299(16):1937-48
pubmed: 18430913
Am J Trop Med Hyg. 2012 Apr;86(4):624-34
pubmed: 22492147
J Microbiol Biotechnol. 2015 Jun;25(6):872-9
pubmed: 25791850
Mol Microbiol. 1994 Jul;13(1):97-107
pubmed: 7984098
PLoS Negl Trop Dis. 2018 Sep 17;12(9):e0006766
pubmed: 30222749
Lancet Infect Dis. 2018 Dec;18(12):e395-e398
pubmed: 30122439
Trends Parasitol. 2018 Jul;34(7):590-602
pubmed: 29858018
Microb Cell Fact. 2020 Aug 20;19(1):168
pubmed: 32819443
PLoS Negl Trop Dis. 2012;6(11):e1900
pubmed: 23145203
J Microbiol Biotechnol. 2007 Apr;17(4):547-59
pubmed: 18051264
Appl Environ Microbiol. 2006 May;72(5):3435-40
pubmed: 16672488
Lancet. 2018 Jan 20;391(10117):252-265
pubmed: 28882382
Parasitol Int. 2014 Aug;63(4):597-603
pubmed: 24704609
J Food Prot. 2010 May;73(5):888-94
pubmed: 20501040
PLoS Negl Trop Dis. 2013 May 30;7(5):e2247
pubmed: 23738029
Ann Trop Med Parasitol. 2009 Jun;103(4):357-60
pubmed: 19508754
Trends Parasitol. 2004 Oct;20(10):477-81
pubmed: 15363441

Auteurs

Hanchen Li (H)

Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, USA.

Ambily Abraham (A)

Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, USA.

David Gazzola (D)

Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, USA.

Yan Hu (Y)

Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, USA.

Gillian Beamer (G)

Department of Infectious Disease and Global Health, Tufts University, North Grafton, Massachusetts, USA.

Kelly Flanagan (K)

Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, USA.

Ernesto Soto (E)

Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, USA.

Florentina Rus (F)

Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, USA.

Zeynep Mirza (Z)

Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, USA.

Austin Draper (A)

Synthetic Biomanufacturing Facility, Utah State University, Logan, Utah, USA.

Sridhar Vakalapudi (S)

Synthetic Biomanufacturing Facility, Utah State University, Logan, Utah, USA.

Cheryl Stockman (C)

Cummings School of Veterinary Medicine at Tufts University, North Grafton, Massachusetts, USA.

Perry Bain (P)

Cummings School of Veterinary Medicine at Tufts University, North Grafton, Massachusetts, USA.

Joseph F Urban (JF)

United States Department of Agriculture, Agricultural Research Service, Beltsville Human Nutrition Research Center, Diet, Genomics, Immunology Laboratory, Beltsville, Maryland, USA.

Gary R Ostroff (GR)

Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, USA gary.ostroff@umassmed.edu raffi.aroian@umassmed.edu.

Raffi V Aroian (RV)

Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, USA gary.ostroff@umassmed.edu raffi.aroian@umassmed.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH